Приказ основних података о документу

dc.creatorBatinić, Borjanka
dc.creatorRistić, Ivan
dc.creatorŽugić, Milica
dc.creatorBaldwin, David S.
dc.date.accessioned2021-12-23T11:08:33Z
dc.date.available2021-12-23T11:08:33Z
dc.date.issued2021
dc.identifier.issn1664-0640
dc.identifier.urihttp://reff.f.bg.ac.rs/handle/123456789/3413
dc.description.abstractCariprazine is currently approved for the treatment of patients with schizophrenia (USA and EU), and for manic, depressive, and episodes with mixed features in bipolar I disorder (USA): several randomized controlled studies have also explored its efficacy in patients with major depressive disorder. This review summarizes its current therapeutic uses and potential advantages for treating the main symptoms of schizophrenia, bipolar I and major depressive disorder, considering its pharmacodynamic properties, efficacy, and tolerability. Its predominantly D3 receptor preferring affinity, with functional selectivity according to the prevailing neuronal environment, contributes to its efficacy across a wide array of psychopathological symptoms (including reality distortion, disorganized thought, negative symptoms, mood disturbance, anhedonia, and cognitive impairment), and to a favorable side effect profile. Cariprazine may be a “drug of choice” in patients with predominant negative and cognitive symptoms of schizophrenia, as well as those with metabolic syndrome. Further investigation of its relative efficacy when compared to aripiprazole or other active comparators is warranted. Its effectiveness in the treatment of bipolar mania, bipolar I depression and bipolar I episodes with mixed features, with minimal accompanying metabolic changes is well-established. The longer half-life and delayed time to relapse in patients diagnosed with schizophrenia when compared to other second-generation antipsychotics represent other advantages, given the high rates of non-adherence and frequent relapses seen in clinical practice. Its efficacy in overlapping symptom domains in other major psychiatric disorders appears promising.
dc.languageEnglish
dc.publisherFrontiers Media
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceFrontiers in Psychiatry
dc.subjectbipolar I disorder
dc.subjectcariprazine
dc.subjectD3/D2 partial agonist
dc.subjectmajor depressive disorder
dc.subjectschizophrenia
dc.titleTreatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
dc.typearticleen
dc.rights.licenseBY
dc.citation.rankM21
dc.citation.volume12
dc.identifier.doi10.3389/fpsyt.2021.784370
dc.identifier.fulltexthttp://reff.f.bg.ac.rs/bitstream/id/7688/fpsyt-12-784370.pdf
dc.identifier.scopus2-s2.0-85120863864
dc.identifier.wos000727640000001
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу